Blog
RSS FeedPosted by Michael Wonder on 18 Jul 2022
More children now eligible for cystic fibrosis drug
18 July 2022 - Effective today, the Province will pay for the cystic fibrosis drug Trikafta for children aged six to ...
Posted by Michael Wonder on 12 Jul 2022
Alberta expands access to cystic fibrosis drug Trikafta for children 6 to 11
11 July 2022 - Children with cystic fibrosis can now live 'longer, healthier and fuller lives,' says advocate. ...
Posted by Michael Wonder on 18 May 2022
Budget 2022: two year old girl and mum travel to Wellington in hopes of getting funding for devastating spinal illness
19 May 2022 - Dozens of people are travelling to Wellington for the Budget to highlight concerns about sick children ...
Posted by Michael Wonder on 08 Apr 2022
NICE recommends Koselugo for the treatment of neurofibromatosis type 1
8 April 2022 - NICE has recommended AstraZeneca and MSD’s Koselugo (selumetinib) for use by the NHS in England, within ...
Posted by Michael Wonder on 28 Mar 2022
Atidarsagene autotemcel for treating metachromatic leukodystrophy
28 March 2022 - NICE has published evidence-based recommendations on atidarsagene autotemcel (Libmeldy) for treating metachromatic leukodystrophy in children. ...
Posted by Michael Wonder on 03 Feb 2022
Eligible Australian kids 16+ can now get a booster
3 February 2022 - From today, eligible Australians aged 16 and 17 years old will be able to receive a COVID-19 ...
Posted by Michael Wonder on 31 Jan 2022
Health technology assessment of paediatric medicines: European landscape, challenges and opportunities inside the conect4children project
28 January 2022 - This article aims at describing the most relevant elements of the drug development process in the paediatric ...
Posted by Michael Wonder on 30 Jan 2022
How are child specific utility instruments used in decision making in Australia? A review of Pharmaceutical Benefits Advisory Committee public summary documents.
28 January 2022 - Measuring and valuing health-related quality of life in children can be challenging but is an important component ...
Posted by Michael Wonder on 20 Jan 2022
Immunotherapy with blinatumomab improves the chances of survival in very rare childhood blood cancer
20 January 2022 - The Federal Joint Committee (G-BA) today classified the additional benefit of the active ingredient blinatumomab as significant ...
Posted by Michael Wonder on 26 Dec 2021
Children and young people set to benefit from new treatment for peanut allergy
23 December 2021 - Children and young people aged between 4 and 17 with a peanut allergy could be set to ...
Posted by Michael Wonder on 01 Dec 2021
NICE terminates appraisal of new treatment for adolescents with obesity
1 December 2021 - NICE is unable to make a recommendation on liraglutide (Saxenda) for managing obesity in adolescents aged 12 ...
Posted by Michael Wonder on 27 Oct 2021
Audrey Ashman’s bone treatment for rare genetic disease known as XLH denied government subsidy
24 October 2021 - Audrey Ashman loves to ballet dance and plays with her brothers — but she needs a special ...
Posted by Michael Wonder on 09 Sep 2021
NICE recommends treatment for people with juvenile idiopathic arthritis
9 September 2021 - NICE has today published final draft guidance which recommends tofacitinib (Xeljanz; Pfizer) as an option for treating ...
Posted by Michael Wonder on 04 Sep 2021
NICE recommends Novartis’ Cosentyx for children with severe psoriasis
3 September 2021 - NICE has recommended Novartis’ interleukin-17A inhibitor Cosentyx (secukinumab) for the treatment of children and young people ...
Posted by Michael Wonder on 30 Aug 2021
Evrysdi (risdiplam) receives CADTH reimbursement recommendation for some patients with spinal muscular atrophy
30 August 2021 - Roche Canada today announced that the CADTH Canadian Drug Expert Committee has issued its final recommendation ...